Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer.

Autor: Jones BS; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Preventive Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Laboratory Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States., Jerome MS; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Preventive Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Laboratory Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States., Miley D; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Preventive Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Laboratory Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States., Jackson BE; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Preventive Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Laboratory Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States., DeShazo MR; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Preventive Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Laboratory Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States., Reddy VV; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Preventive Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Laboratory Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States., Singh KP; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Preventive Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Laboratory Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States., Brown OC; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Preventive Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Laboratory Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States., Robert F; Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Preventive Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States; Division of Laboratory Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, United States. Electronic address: pacorobertuab@cs.com.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2017 Apr; Vol. 106, pp. 125-130. Date of Electronic Publication: 2017 Feb 09.